68Ga-PSMA-11
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Biochemical Recurrence of Malignant Neoplasm of Prostate
Conditions
Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma
Trial Timeline
Jul 19, 2023 → Jul 30, 2026
NCT ID
NCT05847348About 68Ga-PSMA-11
68Ga-PSMA-11 is a phase 3 stage product being developed by Telix Pharmaceuticals for Biochemical Recurrence of Malignant Neoplasm of Prostate. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05847348. Target conditions include Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma.
What happened to similar drugs?
0 of 1 similar drugs in Biochemical Recurrence of Malignant Neoplasm of Prostate were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07052214 | Phase 3 | Recruiting |
| NCT05847348 | Phase 3 | Recruiting |
Competing Products
3 competing products in Biochemical Recurrence of Malignant Neoplasm of Prostate
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Durvalumab + Olaparib | AstraZeneca | Phase 2 | 27 |
| Darolutamide (BAY1841788, Nubeqa) | Bayer | Phase 3 | 41 |
| Darolutamide(BAY1841788, Nubeqa) + Enzalutamide | Bayer | Phase 2 | 32 |